Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Sonnet BioTherapeutics Holdings, Inc. (BURG)
|
Add to portfolio |
|
|
|
| Price: |
$0.44
| | Metrics |
| OS: |
38.5
|
M
| |
|
|
| Market cap: |
$16.9
|
M
| |
|
|
|
|
|
| |
|
|
|
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
|
|
| |
|
|
|
|
|
| |
|
|
| EPS |
| |
|
|
|
BVPS
|
$0.09
| |
4.95
|
x P/B
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Sep-30-22 | Sep-30-21 | Sep-30-20 | Sep-30-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.3 | 0.5 | 0.0 | 0.0 | 40.6 | 41.4 | 41.7 | 35.4 |
| Revenue growth | -27.6% | | | | -2.0% | -0.6% | 18.0% | 18.5% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 13.3 | 13.7 | 13.4 | 12.0 |
| Gross profit | 0.3 | 0.5 | 0.0 | 0.0 | 27.3 | 27.7 | 28.3 | 23.3 |
| Gross margin | 100.0% | 100.0% | | | 67.3% | 67.0% | 67.8% | 66.0% |
| Selling, general and administrative | | | | | | | | |
| Research and development | 21.4 | 16.6 | 9.9 | 2.2 | | | | |
| General and administrative | 8.6 | 8.9 | 7.5 | 2.5 | 4.6 | 4.5 | 5.8 | 6.8 |
| EBITA | -29.7 | -25.1 | -17.4 | -4.7 | -2.9 | -2.5 | -2.3 | -4.9 |
| EBITA margin | -8478.3% | -5187.4% | | | -7.1% | -6.1% | -5.5% | -13.7% |
| Amortization of intangibles | | | | | 0.5 | 0.3 | 0.3 | 0.2 |
| EBIT | -29.7 | -25.1 | -17.4 | -4.7 | -3.4 | -2.8 | -2.6 | -5.1 |
| EBIT margin | -8478.3% | -5187.4% | | | -8.4% | -6.9% | -6.3% | -14.4% |
| Pre-tax income | -29.7 | -25.0 | -24.3 | -4.9 | -7.9 | -7.8 | -4.1 | 7.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | -0.7 | -0.6 | 0.2 | -0.2 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 8.9% | 8.3% | | |
| Earnings from continuing ops | -29.7 | -25.0 | -65.6 | -4.9 | -7.3 | -7.3 | -7.8 | -12.6 |
| Earnings from discontinued ops | | | | | 0.3 | 0.4 | -1.3 | -1.9 |
| Net income | -29.7 | -25.0 | -65.6 | -4.9 | -7.0 | -6.9 | -9.1 | -14.5 |
| Net margin | -8493.3% | -5166.0% | | | -17.2% | -16.7% | -21.8% | -40.9% |
| |
| Diluted EPS | ($6.84) | ($14.25) | ($6.96) | ($0.91) | ($2.08) | ($2.88) | ($3.58) | ($0.88) |
| Shares outstanding (diluted) | 4.3 | 1.8 | 9.4 | 5.3 | 3.5 | 2.5 | 2.2 | 14.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|